NPJ Precis Oncol. 2023; 7: 58.
Targeting CDK1 in cancer: mechanisms and implications
,
,
and
Qiushi Wang
The Hormel Institute, University of Minnesota, 801 16th Ave NE, Austin, MN 55912 USA
Ann M. Bode
The Hormel Institute, University of Minnesota, 801 16th Ave NE, Austin, MN 55912 USA
Tianshun Zhang
The Hormel Institute, University of Minnesota, 801 16th Ave NE, Austin, MN 55912 USA
The Hormel Institute, University of Minnesota, 801 16th Ave NE, Austin, MN 55912 USA
Corresponding author.
Received 2023 Feb 22; Accepted 2023 May 25.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit
http://creativecommons.org/licenses/by/4.0/.
This article has been
cited by other articles in PMC.
Abstract
Cyclin dependent kinases (CDKs) are serine/threonine kinases that are proposed as promising candidate targets for cancer treatment. These proteins complexed with cyclins play a critical role in cell cycle progression. Most CDKs demonstrate substantially higher expression in cancer tissues compared with normal tissues and, according to the TCGA database, correlate with survival rate in multiple cancer types. Deregulation of CDK1 has been shown to be closely associated with tumorigenesis. CDK1 activation plays a critical role in a wide range of cancer types; and CDK1 phosphorylation of its many substrates greatly influences their function in tumorigenesis. Enrichment of CDK1 interacting proteins with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was conducted to demonstrate that the associated proteins participate in multiple oncogenic pathways. This abundance of evidence clearly supports CDK1 as a promising target for cancer therapy. A number of small molecules targeting CDK1 or multiple CDKs have been developed and evaluated in preclinical studies. Notably, some of these small molecules have also been subjected to human clinical trials. This review evaluates the mechanisms and implications of targeting CDK1 in tumorigenesis and cancer therapy.
Subject terms: Targeted therapies, Chemotherapy
Introduction
Cyclin dependent kinases (CDKs) are serine/threonine kinases that form a complex with cyclin proteins, a process that is essential for full activation of their kinase activity. CDKs play critical roles in the control of cell division and modulation of transcription in response to extracellular and intracellular stimuli1. CDKs are involved in many crucial processes and are associated with several disease conditions, such as Alzheimer’s disease2, Parkinson’s disease3, stroke4, HIV5, and cancer6,7. The CDK protein family comprises twenty kinases (CDK1-20). CDK1-6 and CDK14-18 are involved in cell cycle and CDK7-13 and CDK19-20 are associated with the function of transcription in gene control8,9. CDK1 is the only CDK in mammals that is essential for cell cycle progression10. It promotes the G2/M and G1/S transitions, as well as G1 progression11. Unrestricted cell proliferation, an indicator of malignancy, is normally driven by alterations in CDK1 activity. The expression of CDKs fluctuates cyclically throughout the cell cycle12. Cancer is a disease of abnormal cell proliferation and occurs when cells evade normal growth or division restrictions. Oncogenic transformation often entails derangement of the mechanisms that ensure the stable inheritance of genes and chromosomes during mitotic cell division13. CDKs play important roles in both the commitment to cell division and the quality control mechanisms that safeguard genome integrity. They represent obvious, but potentially risky, therapeutic targets in treating human cancers14. In addition to presenting the frequency of overexpression in different cancer types, CDKs have been shown to function as oncogenes or were identified as frequently overexpressed secondary oncogenes in several types of cancer, including melanoma and lung cancer. In these cancers, CDKs are not the primary drivers of cancer but are overexpressed in conjunction with other oncogenes15–17. For instance, CDKs are highly expressed in non-small cell lung cancer with EGFR mutations16. CDK/cyclin activity is mediated by physiological CDK inhibitors or CKIs. Over the last decade, substantial progress has been made in discovering and developing novel small molecule CKIs18–22. This area of drug discovery has adopted novel research strategies that are different from the classic reversible ATP competitive or non-competitive action modes. Traditional kinase inhibitory molecules include irreversible ATP competitive drugs, reversible and irreversible structural inhibitors, CDK degrading drugs, and inhibitory CDK binding antibodies. Newer drugs have opened an avenue to interrogate, for example, new and more challenging transcriptional CDK targets22. A number of selective inhibitors or pan-inhibitors of CDK1 have been produced over past decades. Inhibition of the expression and activation of CDK1 effectively suppresses oncogenic cell function in many cancer types. Notably, some small molecules targeting CDK1 have already been studied in clinical trials. In this review, we evaluate the critical role and mechanisms of CDK1 in tumorigenesis. Additionally, we examine the current CDK1 inhibitors that have been evaluated in preclinical and clinical studies for cancer therapy.
CDK expression in cancer
According to The Cancer Genome Atlas (TCGA) UALCAN database23,24, CDKs are significantly upregulated in many cancerous tissues compared to normal tissues, indicating a widespread increase in their expression. (Fig. , Supplementary Table 1, Supplementary Fig. 1). Based on these results, CDK1, CDK2, CDK4, CDK5, and CDK7 are the top 5 CDKs that are highly expressed in cancer tissues compared to normal tissues. Overall, compared with normal tissues, the expression of CDK4 and CDK5 are higher in 18 out of 24 or 75% of the cancers listed. CDK1 is significantly higher in 17 out of 24 or 70.8% of the cancers listed and CDK2 and CDK7 are higher in 16 out of 24 or 67% of the cancers listed.
In addition, information from the database indicates that high expression of CDKs is closely correlated with the overall survival rate in 32 different cancer types (Supplementary Table 1, Fig. ). Overall, the data indicate that the top 5 CDKs, CDK1 (11/32 or 34.4%), CDK2 (10 /32 or 31.3%), CDK6 (8/32 or 25%), CDK7 (9/32 or 28.1%), and CDK19 (8/32 or 25%), are closely associated with survival probability in various cancers.
CDKs are highly expressed in cancer tissues and closely associated with survival probability in multiple cancer types. Collectively, these results indicate that targeting CDKs, and especially CDK1, could be a critical strategy for cancer treatment. The remainder of this review focuses on mediators, substrates, and inhibitors of CDK1 in cancer.
Upstream mediators of CDK1
The upstream modulators of CDK1 (Supplementary Table 2) in cancer include various molecular factors that can positively or negatively influence CDK1 activation, amplification, transcription, and expression.
Positive upstream modulators of CDK1
Activators of CDK1
CDK1 is essential for cell division during mitosis. It helps form the spindle and aligns chromosomes by recruiting and activating key proteins involved in kinetochore formation. CDK1 activity ensures proper chromosome orientation and segregation and is critical for the successful assembly of the mitotic apparatus and chromosome alignment. The activation of CDK1 requires phosphorylation on Thr161 or dephosphorylation on Thr14 and Tyr1525,26. CDK7 mediates G1 cell cycle arrest and extrinsic apoptosis by increasing phosphorylation of CDK1 at Thr16127. Protein tyrosine phosphatase receptor type F (LAR) also increases focal adhesion by enhancing CDK1 activation at Thr16128. Nucleolar protein 11 (NOL11) and CDK5 regulatory subunit associated protein 3 (C53) delay cell entry into mitotic phase though dephosphorylation of CDK1 on Tyr1529,30. Cell division cycle 25 (CDC25) is a dual-specificity phosphatase, which counteracts G2/M checkpoint activation by removing inhibitory phosphate groups (Thr14 or Tyr15) from CDK1 and are themselves negatively modulated by checkpoint kinase 1 (CHK1)31. CDC25 proteins include CDC25A, CDC 25B, and CDC 25C. They mediate meiosis through activation of CDK1 by dephosphorylation on Thr14 and Tyr1527,32–35. Associated with CDC25 mediation of activation of CDK1 are several molecules, including CDK2, beclin 1 (BECN1), tetramerization domain containing 12 (KCTD12), nucleophosmin (NPM), and minichromosome maintenance 10 replication initiation factor (MCM10), each of which facilitates activation of CDK1 by mediating CDC25 activity36–43. For example, BECN1 translocases into the nucleus, where it interacts with CDC25C and CHK2, resulting in promotion of radiation-induced G2/M arrest through promotion of CDK1 activity40. Additionally, other molecules, such as Aurora A kinase (AURKA)44, 6-phosphofructo-2-kinase (PFKFB3)45, ubiquitin C-terminal hydrolase L1 (UCH-L1)46, microtubule-associated serine/threonine kinase-like (MASTL)47, testis-specific protein Y-encoded (TSPY)48, karyopherin subunit beta 1 (KPNB1)49, and STIL centriolar assembly protein (SIL), all promote CDK1 activity (Supplementary Table 2)50.
Transcriptional modulation of CDK1 and upregulation of CDK1 expression (Supplementary Table 2)
E2F transcription factor (E2F)-dependent transcription controls both G1/S- and G2/M-associated genes. Specifically, E2F1, E2F2, and E2F3 enhance CDK1 transcription by binding to the positive-acting E2F site in the CDK1 promoter, which results in increased CDK1 expression51. Mortality factor 4 like 1 (MRG15), a chromatin modulator, is a highly conserved protein present in complexes containing histone acetyltransferases (HATs), as well as histone deacetylases (HDACs). MRG15 acts in the HAT complex through its acetylation of histone H4 at the CDK1 promoter to activate transcription52. The cysteine-rich CXC domain of Lin-54 DREAM MuvB core complex component (LIN54) is a novel DNA-binding domain that binds to the CDK1 promoter in a sequence-specific manner53. Besides directly binding with the CDK1 promoter, several molecules also modulate CDK1 transcriptional activation. For example, CDK1 is a direct transcriptional target of centromere-associated protein E (CENPE) in primary pulmonary artery smooth muscle cells. The overexpression of CENPE significantly increases CDK1 promoter activity, whereas the deletion of CENPE markedly decreases promotor activity54, which attenuates CDK expression. Sp1 transcription factor (SP1), initially identified as a transcription factor, plays a crucial role in normal biological processes, neoplastic development, and tumor migration55. Dual-luciferase reporter assay results showed the direct effect of SP1 on the transcriptional activation of CDK156. Knockdown of ribosomal protein S9 (RPS9) inhibits the growth of human colon cancer cells at the G2/M phase by downregulating CDK1 expression at the promoter level57.
Several molecules enhance tumor cell growth, migration, or invasion by upregulating the expression of CDK1 in different ways. Among them, chondroitin polymerizing factor (CHPF), co-stimulatory molecule (CD276), and papillomavirus E6 (E6) enhance CDK1 expression by increasing the expression of transcription factor E2F1. Knocking down expression of CHPF or CD276 maintains proliferation or modulates differentiation by mediating E2F1/CDK1 expression in malignant melanoma and endothelial progenitor cells, respectively58,59. NOP2/sun RNA methyltransferase 2 (NSUN2) and death-associated protein 5 (DAP5) promote CDK1 expression by enhancing CDK1 translation60–62. NSUN2 methylates CDK1 mRNA in vitro and in cells, and that methylation by NSUN2 enhances CDK1 translation influencing cell growth and survival during mitosis60,61. Oncogenic action of RNA binding motif protein 7 (RBM7) and histone deacetylase 6 (HDAC3) controls cell progression by stabilizing CDK1 mRNA and protein levels, respectively. RBM7 directly binds to the AU-rich elements (AREs) in the 3’-UTR of CDK1 mRNA, which contributes to the stability of CDK1 mRNA by lengthening CDK1 half-life in breast cancer63. HDAC3 mediates G2/M phase progression mainly through post translational stabilization of the CDK1 protein by controlling CDK1 ubiquitination64. Somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) have been identified in approximately 25% of patients with LAML DNMT3A mutation that occurs in the early stages of LAML and is regarded as a pre-leukemic gene mutation65. DNMT3A mutation can induce CDK1 overexpression and promote leukemogenesis66. Additionally, several other molecules also mediate cell proliferation, metastasis, or survival by enhancing CDK1 expression (Supplementary Table 2).
Negative upstream modulators of CDK1
Mediators that decrease activation of CDK1
Many molecules markedly upregulate the activity of CDK1 in tumorigenesis, whereas negative upstream mediators of CDK1 also widely exist. These negative modulators are usually tumor suppressors that inhibit CDK1 activation in tumor progression. As indicated earlier, dephosphorylation on Thr14 and Tyr15 or phosphorylation at Thr161 is required for the full activation of CDK125. Wee1-like protein kinase 1 (WEE1)67–69 and membrane associated tyrosine/threonine 1 (MYT1) kinase70–72 inhibit CDK1 activation by phosphorylation at Thr14 and Tyr15, and this modification plays a crucial role in the G2–M cell-cycle checkpoint arrest for DNA repair before mitotic entry73. Besides these two important kinases, many other key molecules also inhibit CDK1 activation by phosphorylation of Thr14 and Tyr15 or dephosphorylation of Thr161 (Supplementary Table 2). For example, phosphatase and tensin homolog (PTEN) is one of the most important and well-studied tumor suppressor proteins. Downregulation of PTEN by siRNA in cells increases phospho-WEE1 (Ser642), but decreases phospho-CDK1 (Tyr15), resulting in decreased G2/M cell cycle arrest74. Dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) demonstrates its tumor suppressive function by mediating phosphorylation of Tyr15 and Thr161 in glioblastoma cells75. CDC25 is known to activate CDK1 by dephosphorylating residues Thr14 and Tyr1531. Checkpoint kinase 1 (CHEK1), one of the critical transducers in DNA damage/replication checkpoints, prevents entry into mitosis through its inhibition of CDC25 and CDK1 activity76,77. Fibroblast growth factor 1 (FGF1) also causes dephosphorylation of the CDC25C phosphatase inducing inactivation of the cyclin B1/CDK1 complex. Kinesin family member 22 (KIF22) is a microtubule-dependent molecular motor protein with DNA-binding capacity. CDC25C is a direct transcriptional target of KIF22 and inhibition of KIF22 increases CDC25C expression and cyclin-dependent kinase 1 (CDK1) activity, resulting in delayed mitotic exit78. Other proteins can also affect CDK1 activity but with no effect on phosphorylation of Thr14 and Tyr15 or dephosphorylation of Thr161. For example, death effector domain containing (DEDD) protein participates in apoptosis signaling, which inhibits activation of CDK1 but does not affect the phosphorylation status at Thr14, Tyr15, or Thr16179,80. Apart from these proteins, several other molecules can also inhibit CDK1 activation (Supplementary Table 2).
Mediators that decrease CDK1 expression and nuclear translocation
In addition to CDK1 activation, CDK1 expression is also tightly modulated. Eukaryotic cells utilize two major routes to effectively target a wide range of proteins for degradation, including the ubiquitin/proteasome system and the autophagy/lysosome pathway81. Double-stranded RNA-activated protein kinase (PKR) is a serine/threonine interferon (IFN)-inducible kinase that plays an important role in the regulation of gene expression at both transcriptional and translational levels. PKR-mediated Tyr4-phosphorylation facilitates CDK1 ubiquitination and proteasomal degradation82. CDK1 accumulation in patients’ tumors shows a negative correlation with beta-transducing repeat containing E3 ubiquitin protein ligase (BTRC) and exhibits a positive correlation with the degree of tumor malignancy. BTRC controls the lysosome-mediated degradation of CDK1, the accumulation of which correlates with tumor malignancy83. Histone deacetylase 6 (HDAC6) plays a dual role in the autophagy/lysosome pathway. It controls the fusion of autophagosomes to lysosomes by promoting F-actin remodeling in a cortactin-dependent manner84. In contrast, upon proteasome inhibition, HDAC6 is recruited and relocates to polyubiquitin-positive aggresomes85. Ubiquitin-binding protein P62 (P62) is a key protein in the autophagic clearance of polyubiquitinated proteins86. CDK1 degradation reportedly involves p62/HDAC6-mediated selective autophagy87. Additionally, the TNF-like WEAK inducer of apoptosis (TWEAK)88, human enhancer of invasion, clone 10 (HEI10)89, and sialophorin (SPN)90 also mediate CDK1 expression by inducing CDK1 degradation, inhibiting CDK1 expression or nuclear translocation (Supplementary Table 2).
Downstream substrates of CDK1
As a serine/threonine protein kinase, CDK1 is reported to phosphorylate a number of substrates, including both tumor promotors and tumor suppressors (Supplementary Table 3).
CDK1 tumor promotor substrates
Increasing evidence suggests that CDK1 phosphorylates downstream substrates that play critical roles in cancer progression signaling pathways. The B-Raf proto-oncogene, serine/threonine kinase (BRAF), as a critical activator of the mitogen-activated protein kinase (MAPK) cascade during mitosis. CDK1/cyclin B directly phosphorylates BRAF at Ser144, which is required for mitotic activation and subsequent activation of the MAPK cascade91. Extracellular signal regulated kinase 3 (ERK3) is an atypical MAPK that is suggested to play a role in cell cycle progression and cellular differentiation. CDK1 can also phosphorylate ERK3 at Thr698, which acts in a cell-cycle-dependent manner92. Androgen receptor (AR) is the principal molecule in prostate cancer etiology and therapy and its re-activation remains a major challenge during treatment of prostate tumors that relapse after castration therapies. CDK1 phosphorylates the AR at Ser81 or Ser515 promoting prostate tumor progression93–95. Hypoxia-inducible factor 1α (HIF1A) is a major mediator of tumor physiology, and its activation is correlated with tumor progression, metastasis, and therapeutic resistance96,97. CDK1 stabilizes HIF1A through direct phosphorylation of Ser668 to promote tumor growth98. YAP is a downstream effector of the Hippo pathway of cell-cycle control that plays important roles in tumorigenesis. CDK1 phosphorylates YAP promoting mitotic defects and cell motility and is essential for neoplastic transformation99. TAZ is also a downstream effector of the Hippo pathway, which plays important roles in cancer and stem cell biology. CDK1 phosphorylation of TAZ in mitosis inhibits its oncogenic activity100. Additionally, the adaptor protein, ajuba LIM protein (AJUBA), is a positive mediator of YAP oncogenic activity. CDK1 phosphorylates AJUBA at Ser119 and Ser175 during the G2/M phase of the cell cycle promoting proliferation and tumorigenesis101. Besides these, other downstream oncoprotein substrates of CDK1 (Supplementary Table 3) participate in multiple signaling pathways mediating tumor progression.
Several CDK1 substrates are oncogenic transcription factors. For example, forkhead box M1B (FOXM1B) transcriptional activity requires binding of either S or M phase CDK/cyclin complexes to mediate efficient CDK1 phosphorylation of the FoxM1B Thr596 residue, which is essential for recruitment of CREB binding protein coactivator proteins102. Phosphorylation of islet-1 (ISL1) at Ser269 by CDK1 increases its transcriptional activity and promotes cell proliferation in gastric cancer103. Mammalian target of rapamycin (mTOR)-directed eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation promotes cap-dependent translation and tumorigenesis. CDK1-directed phosphorylation of 4E-BP1 may yield a gain of function activity, distinct from translational regulation, which may be important in tumorigenesis and mitotic centrosome function104. The activating transcription factors (ATFs) belong to the activator protein 1 (AP-1) family of transcription factors105. Phosphorylation of ATF7 by CDK1 at Thr51 or Thr53 in M phase is required for G2/M progression106. Additionally, RUNX family transcription factor 1 (RUNX1)107, RUNX2108, retinoid X receptor alpha (RXRA)109, CCAAT enhancer binding protein alpha (CEBPA)110, transcription factor CP2 like 1 (TFCP2L1)111, and octamer-binding transcription factor 4 (OCT4)112,113 are also oncogenic transcription factors mediated by CDK1 (Supplementary Table 3).
Apart from these CDK1 substrates, BCL2 apoptosis regulator (BCL2), BCL2 apoptosis regulator like 1 (BCL2L1), and dynamin 1 Like (DRP1) are phosphorylated by CDK1, mediating mitochondrial fusion and apoptosis in human cancer cells114–121. F-box protein 28 (FBXO28) and carboxypeptidase D (CPD) are phosphorylated by CDK1 increasing ubiquitylation promoting tumorigenesis. FBXO28 ubiquitin ligases act as one of the master regulators of cellular homeostasis by targeting key proteins for ubiquitylation. FBXO28 activity and stability are regulated during the cell cycle by CDK1/2 phosphorylation, which is required for its efficient ubiquitylation of MYC and downstream enhancement of the MYC pathway. CDK1-mediates activation of the FBXO28 ubiquitin ligase promotes MYC-driven transcription and tumorigenesis and predicts poor survival in breast cancer122. A GATA family transcription factor, GATA-binding protein 2 (GATA2), participates in cell growth and differentiation of various cells. GATA2 contains CPD, a consensus motif for ubiquitylation that includes Thr176. CDK1 phosphorylates CPD at Thr176, which increases GATA2 expression levels123. Moreover, several additional molecules also demonstrate ontogenetic function mediated by CDK1 (Supplementary Table 3).
CDK1 tumor suppressor substrates
The tumor suppressor p53, an important CDK1 substrate, plays critical roles in a diversity of physiologic functions by increasing genomic stability, inhibiting cell transformation, and initiating apoptosis when DNA damage repair is defective124. Cyclin B1/CDK1-mediated Ser315 phosphorylation in p53-wild-type tumor cells may provide insights for improving the efficacy of anti-cancer therapy125. Moreover, the tumor protein p73 transcription factor is a member of the p53 family and participates in developmental processes and the DNA damage response. CDK1-dependent Thr86 phosphorylation represses the ability of p73 to induce endogenous p21 expression126. The forkhead box O (FOXO) transcription factor FOXO1 functions as a tumor suppressor by mediating apoptosis, cell cycle arrest, and oxidative detoxification. CDK1 may contribute to tumorigenesis by promoting cell proliferation and survival through phosphorylation and inhibition of FOXO1127,128. Additionally, tumor suppressors caspase 8 (CASP8) and caspase 9 (CASP9) are phosphorylated by CDK1 facilitating apoptosis in cancer cells129,130. Some other CDK1 substrates act as tumor suppressors, including discs large MAGUK scaffold protein 1 (DLG1)131, F-box protein 5 (EMI1)132, sequestosome 1 (P62)133, EPH receptor A2 (EPHA2)134,135, and vestigial like family member 4 (VGLL4)136. They influence tumor progression through multiple signaling pathways, including the APC, Ras/MAPK, and Hippo pathways. Besides these tumor suppressors, receptor-associated protein 80 (RAP80), inhibitor of growth family member 1 (ING1), and EMAP Like 2 (EML2) are also phosphorylated by CDK1 mediating DNA damage, cell proliferation, and migration137,138 (Supplementary Table 3).
CDK1 cell cycle substrates
The cell cycle consists of the mitotic (M) phase and interphases, G1, S, and G2. CDK1 functions during the entire cell cycle by phosphorylating its various substrates. CDK1 is the major protein kinase that drives cells into mitosis139. CDK1 phosphorylates multiple substrates including aurora kinase activator (BORA)140, mixed lineage leukemia-5 (MLL5)141, and greatwall (GWL)142, which all have a critical role in mitotic entry. CDK1 also acts as a mediator in mitotic exit by phosphorylation of cell division cycle associated 5 (CDCA5)143, and centromere protein A (CENPA)144. M phase consists of four basic phases including prophase, metaphase, anaphase, and telophase. CDK1 phosphorylates non-SMC condensin II complex subunit D3 (CAPD3) at Thr1415, which is required for timely chromosome condensation during prophase145. Checkpoint kinase 2 (CHK2) is an essential protein kinase governing DNA damage and replication stress checkpoints. CDK1 phosphorylates CHK2 kinase in metaphase, influencing cellular morphogenesis146. The spindle and kinetochore associated complex subunit 3 (SKA3) protein complex is required for accurate chromosome segregation during mitosis147. SKA3 is phosphorylated by CDK1 in mitosis to promote the onset of anaphase148. CDK1 phosphorylates 4E-BP1 at Ser83, which accumulates at centrosomes during prophase, peaks at metaphase, and decreases through telophase104. Besides these, CDK1 also phosphorylates several other substrates during M phase by mediating multiple functions including spindle assembly, microtubule dynamics, and completion of cytokinesis (Supplementary Table 3). Overall, the substrates of CDK1 are critical in M phase for efficient cell division.
Following M phase, CDK1 substrates also function in the interphases of cell cycle. Fatty acyl-CoA reductase 1 (FAR1) transcription is maximal between mitosis and early G1 phase. Phosphorylation (Ser87) by CDK1 primes FAR1 for ubiquitin-mediated proteolysis149. At entry into S phase, CDK1 phosphorylates WRN recQ like helicase (WRN)150, cell division cycle 7 (CDC7)151, BRCA1 DNA repair associated (BRCA1)152, and RAD9 checkpoint clamp component A (RAD9)153, influencing DNA replication and checkpoint control. In particular, CDK1-mediated phosphorylation of BRACA1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage152. Telomeric repeat factor 1 (TRF1), a duplex telomeric DNA-binding protein, plays an important role in telomere metabolism. CDK1 phosphorites TRF1, which is recruited to sites of DNA damage to facilitate homologous recombination and checkpoint activation at the S/G2 phase154. Additionally, CDK1 phosphorylates ELAV like RNA binding protein 1 (ELAVL1) during G2, thereby helping to retain it in the nucleus hindering its post-transcriptional function and anti-apoptotic influence155. Besides these, several other molecules also play important roles in cell cycle progression (Supplementary Table 3).
CDK1 interactome and related signaling pathways
CDK1 participates in tumorigenesis by interacting with many proteins (Supplementary Tables 2 and 3) that have functions in multiple signal pathways. We performed Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of potential signaling pathways associated with CDK1 interacting proteins. We used the KEGG rest API (https://www.kegg.jp/kegg/rest/keggapi.html) to obtain the latest gene annotations of the KEGG pathway. The enrichment analysis was performed using the R software package, clusterProfiler (v3.14.3), to obtain results of gene set enrichment. An FDR of <0.05 was considered statistically significant. The results indicate that CDK1 integrating proteins are involved in signaling pathways in cancer, cell cycle, and microRNAs. Ten top pathways (Fig. ) were identified. Using Metascape, we then selected a subset of representative terms and converted them into a network layout156. More specifically, each term is represented by a circle node, where its size is proportional to the number of input genes falling under that term, and its color represents its cluster identity (i.e., nodes of the same color belong to the same cluster). Terms with a similarity score > 0.3 are linked by an edge and the thickness of the edge represents the similarity score. The network is visualized with Cytoscape (v3.1.2) with “force-directed” layout and with edge bundled for clarity. One term from each cluster is selected to have its term description shown as a label (Fig. ). The same enrichment network has its nodes colored by the p value, as shown in the legend. The darker the color, the more statistically significant the node is (see legend for p value ranges, Fig. ). Based on the metanalysis results, signal pathways in cancer, cell cycle, and microRNAs in cancer are the top 3 pathways associated with CDK1 interacting proteins. Using the STRING database, we then obtained the interacting network of CDK1 and its interacting proteins in pathways in cancer (Fig. ). Collectively, CDK1 is clearly involved in multiple cancer-related pathways, suggesting the significance of CDK1 in various cancer processes.
Signaling pathways associated with CDK interacting proteins.A Signaling pathways involving CDK1-interacting proteins are identified by KEGG pathway enrichment analyses. Pathways in cancer, cell cycle, and microRNAs and ten top pathways are shown by bubble chart. An FDR of <0.05 was considered statistically significant. B KEGG pathway enrichment analyses cluster plot showing a chord dendrogram of the clustering of the expression spectrum of the proteins involve in ten top pathways. C The network is visualized by using Cytoscape with “force-directed” layout and with edge bundled for clarity. One term from each cluster is selected to have its description shown as the label. D The same enrichment network has its nodes colored by p value, as shown in the legend. The darker the color, the more statistically significant is the node (see legend for p value ranges). E The interacting network of CDK1 and its interacting proteins in Pathways in cancer are demonstrated by using the STRING (https://string-db.org/).
Targeting CDK1 provides a potential strategy for attenuating cancer development
This review thus far has examined the critical role of CDK1 in cancer. The accumulated findings demonstrate that CDK1 could be a potential target for cancer prevention and therapy. In recent years, several small molecules with anticancer activity that target CDK1 and other CDKs have been identified in preclinical and clinical studies focusing on multiple cancer types. The effects of various CDK1 associated CKIs in cancer are summarized in Supplementary Tables 4 and 5.
Targeting CDK1 in preclinical studies
RO-3306157–159 and CGP-74514A160,161 are specific CDK1 inhibitors that effectively suppress the growth of cancer cells and patient derived xenografts (PDX). Additionally, the pan-CDK inhibitors have shown anticancer activity in preclinical studies (Supplementary Table 4).
Targeting CDK1 in clinical studies
CDKs are attractive targets against cancer and CDK inhibitors have been studied since the 1990s. Also, various clinical trials have investigated the use of CDK inhibitors in order to improve treatment of patients with virous cancer types (Supplementary Table 5). Some of the more notable inhibitors are discussed below.
BEY1107
BEY1107 (avotaciclib) is an orally active CDK1 inhibitor. A phase 1/2 clinical trial has assessed the maximum tolerated dose, safety, and efficacy of BEY1107. It is proposed to be used as a monotherapy and in combination with gemcitabine in patients with locally advanced or metastatic pancreatic cancer162.
Flavopiridol
Flavopiridol (alvocidib) is a pan-CDK inhibitor that suppresses CDK1, CDK2, CDK4, CDK6, CDK7, and CDK9 with IC50s of 30, 170, 100, 60, 300, and 10
nM, respectively. Several clinical trials have been conducted for the treatment of leukemia163, multiple myeloma164, sarcoma, gastrointestinal stromal tumor, and other solid tumors. Flavopiridol has received “orphan drug” designation from the FDA for LAML165. Previous preclinical studies suggested that flavopiridol can inhibit cancer development166,167. Unfortunately, it showed less efficacy in human clinical studies. In particular, flavopiridol at this dose and schedule does not have single-agent activity in patients with colorectal cancer. Trials that evaluate flavopiridol in combination with active cytotoxic drugs should help to define the role of this novel agent in colorectal cancer168. Additionally, flavopiridol also exhibited certain side effects in the clinical trial. Flavopiridol as a single agent given by bolus and then infusion caused significant diarrhea, cytopenias, and transaminase elevation, but only achieved marginal responses in relapsed myeloma164. To decrease the side effects, the combination of flavopiridol with other anticancer drugs might be an effective way to enhance its efficacy169.
Roniciclib
Roniciclib (BAY1000394) is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5–25nM for CDK1, CDK2, CDK3, CDK4, CDK7, and CDK9. Roniciclib has been used in several clinical trials of various neoplasms and lung cancer. Based on a Phase 1 dose-escalation study of roniciclib in advanced malignancies, Roniciclib demonstrated an acceptable safety profile and moderate disease control rate in 3 days on/4 days off schedule170. Roniciclib co-administered with chemotherapy in patients with extensive-disease small-cell lung cancer (ED-SCLC) demonstrated tolerability, acceptable pharmacokinetics, and promising efficacy. Unfortunately, an observed safety signal in a related phase 2 study resulted in discontinuation of the present study and termination of further development of roniciclib171,172.
P276-00
P276-00 (Riviciclib) is a potent CDK inhibitor and suppresses CDK1, CDK4, CDK9 activity with IC50s of 79, 63, and 20nM, respectively. A phase 1 study was designed to determine the maximum tolerated dose, toxicity profile, pharmacokinetics, and anti-cancer activity of P276–00 given intravenously to patients with advanced refractory neoplasms13,173. Additional clinical studies evaluated efficacy of P276-00 in subjects with advanced malignant melanoma positive for cyclin D1 expression, advanced triple negative breast cancer, and advanced head and neck cancer13,174. Notably, a Phase 2, single-arm, open-label, multicenter study evaluated the efficacy and safety of P276-00 in patients with relapsed or refractory mantle cell lymphoma. Of the 13 patients, 11 experienced disease progression, 1 patient was withdrawn because of an adverse event, and 1 patient died. Given the results observed in the present study, if evaluation of CDK inhibition in MCL continues, it should be considered earlier in the disease course or as a part of combination strategies for relapsed or refractory disease175. These results suggest the anticancer efficacy of P276-00; however, further investigations are still needed to confirm the anticancer effects and safety.
Dinaciclib
Dinaciclib (SCH727965) is a broad spectrum and competitive inhibitor of CDKs. It can inhibit CDK1, CDK2, CDK5, and CDK9 with IC50s of 3, 1, 1, and 4nM, respectively. Dinaciclib has been used in several clinical trials to treat multiple cancer types such as pancreatic cancer, non-small-cell lung cancer, neoplasms, leukemia, breast cancer, myeloma, lymphoma and melanoma. Dinaciclib has demonstrated inhibitory effects in several clinical studies and showed significant clinical activity against relapsed and refractory chronic lymphocytic leukemia. Positive responses occurred in 28 (54%) of patients with a median progression-free survival of 481 days176. Another study demonstrated single agent activity of dinaciclib against relapsed myeloma177. The same study also showed that dinaciclib treatment demonstrated antitumor activity in 2 of 7 patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (1 confirmed and 1 unconfirmed partial response), as well as acceptable safety and tolerability178. All these results suggested that dinaciclib is a promising CDK1-associated inhibitor for clinical treatment of cancer.
AT7519
AT7519 (AT7519M) is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and 10nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively. AT7519 shows encouraging anticancer activity against multiple cancer cell lines and tumor xenografts179,180. AT7519 has also been evaluated in several clinical trials, including lymphoma and unspecified adult solid tumors, multiple myeloma, and leukemia. A phase 1 study of AT7519 was conducted to evaluate the safety and tolerability. The preliminary anticancer activity was observed with AT7519 at 27.0mg/m2181. Additionally, promising preliminary clinical activity was observed when AT7519 was combined with the HSP90 inhibitor onalespib182. Collectively, AT7519 is also another promising CDK1-associated inhibitor for cancer treatment in the clinic.
Other CDK1 inhibitors
Seliciclib (Roscovitine), AG-024322, PHA-793887, R547, RGB-286638, AZD-5438, and Indirubin (Couroupitine B) exhibited potential for clinical application (Supplementary Table 5). However, assessment of the safety and antitumor activity is still needed in future studies.
Limitation and potential of targeting CDK1
CDK1-associated inhibitors might replace traditional endocrine therapies in many situations. However, adverse side effects183,184 and less efficacy185–187 are still limitations for clinical application. Because CDKs play important roles in normal cellular processes, targeting them can lead to unintended consequences, such as toxicity and other adverse effects. Comprehensively understanding the mechanisms by which CDKs contribute to cancer and normal cell functions is crucial to balance the potential benefits of CDK inhibitors with their risks and toxicities. Designing CDK inhibitors that selectively target cancer cells while minimizing toxicity to normal cells requires intricate knowledge of CDK regulation. To address the limitations of CDK inhibitors, combination treatment with other anti-cancer agents might be best use in cancer treatment. Highlighting the distinct regulatory mechanisms of CDK1 activity in different cancer types can enhance precision oncology and enable successful combinatorial treatment with CDK1 inhibitors188–190. For instance, CDK1 inhibition can be a potential therapy for MYC-dependent breast cancer188. In the clinical application, the toxicities are manageable and clinical activity was observed when flavopiridol in combination with paclitaxel in patients with esophagus, lung, and prostate cancer169. The pan-CDK1 inhibitor dinaciclib in combination with rituximab, an anti-CD20 monoclonal antibody, was well tolerated and revealed encouraging clinical activity in relapsed/refractory chronic lymphocytic leukemia patients191. In addition, promising preliminary clinical activity has been observed in a Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors182. Furthermore, several clinical trials of CDK1 associated inhibitors combining with other anti-cancer agents are ongoing to evaluate the combination treatment in cancer (NCT03579836; NCT03484520; NCT01434316; NCT01676753). These clinical studies will provide more information for the combination of CDK1 associated inhibitors with other anti-cancer agents for cancer treatment.
Besides side effects, several clinical trials indicated that CDK1-associated inhibitors failed to demonstrate sufficient efficacy in cancer patients185–187. The preclinical data suggest that the lack of efficacy of CDK1 associated inhibitors might be associated with poor pharmacokinetics of the drugs192,193. In addition, clinical trials performed on some cancer patients failed to respond to treatment because of low expression levels of CDK1. Another possible reason for the lack of efficacy could be related to advanced stage of tumor progression enabling more resistance to therapy in general. To improve these issues, screening of patients with high CDK1 expression is important for recruiting patients. Additionally, combination therapy should also be an effective approach to enhance the efficacy of CDK1-associated inhibitors in clinical trials.
Summary
In this review, we focused on the role the CDK1 in cancer and examined the potential application of targeting CDK1 for cancer treatment. We demonstrated the expression level and associated survival rate of CDKs in multiple cancer types. The results suggest that CDK1 is a promising target protein in various cancers. We also examined proteins that interact and mediate CDK1 or are mediated by CDK1. Our analysis demonstrated that CDK1-associated proteins play a critical role in multiple cancer signaling pathways. These results provide evidence of clinical benefits of CKIs. A series of preclinical studies have shown that CKIs mediate various cancer cell processes including proliferation, apoptosis, invasion, and metastasis. Importantly, several preclinical animal studies and clinical studies demonstrated the efficacy of CKIs in cancer treatment. These results are summarized in Fig. and suggest potential opportunities for targeting CDK1 as a cancer treatment.
Schematic diagram illustrating the CDK1-associated mediators in cancer.CDK1 expression is regulated at either transcriptional or post-transcriptional levels and CDK1 activity is tightly controlled by numerous molecules. Once activated, CDK1 interacts with and phosphorylates a wide variety of proteins serving as oncogenes, tumor suppressors, or substrates in cell cycle. Selective CKIs and pan-CDK1 have been developed and studied in preclinical or clinical evaluation.
Overall, this review summarized the function and mechanism of CDK1 in cancer. Targeting CDK1 might provide opportunities for cancer prevention and therapy. The combined CDK1 associated inhibitors with other anticancer agents might improve the chemotherapeutic benefits and improve clinical outcome in cancer development. Future studies are required to determine these issues194–336.
Supplementary information
Acknowledgements
The authors would like to acknowledge The Hormel Foundation and the National 1P01CA229112-01A1 Institutes of Health grant for financial support.
Author contributions
Q.W. and T.Z. conducted a comprehensive literature search, summarized the findings, and drafted the manuscript. A.M.B. provided critical revisions and feedback to enhance the manuscript. T.Z. designed the study. All authors participated in revisions and gave final approval to the manuscript.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
The online version contains supplementary material available at 10.1038/s41698-023-00407-7.
References
2.
Malhotra N, Gupta R, Kumar P. Pharmacological relevance of CDK inhibitors in Alzheimer’s disease. Neurochem. Int. 2021;148:105115. 10.1016/j.neuint.2021.105115. [Abstract] [CrossRef] [Google Scholar]3.
Alquézar C, et al. Targeting cyclin D3/CDK 6 activity for treatment of Parkinson’s disease. J. Neurochem. 2015;133:886–897. 10.1111/jnc.13070. [Abstract] [CrossRef] [Google Scholar]7.
Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in cancer therapy: current evidence and future directions. Target. Oncol. 2018;13:21–38. 10.1007/s11523-017-0541-2. [Abstract] [CrossRef] [Google Scholar]9.
Liu J, Kipreos ET. Evolution of cyclin-dependent kinases (CDKs) and CDK-activating kinases (CAKs): differential conservation of CAKs in yeast and metazoa. Mol. Biol. Evol. 2000;17:1061–1074. 10.1093/oxfordjournals.molbev.a026387. [Abstract] [CrossRef] [Google Scholar]10.
Santamaría D, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448:811–815. 10.1038/nature06046. [Abstract] [CrossRef] [Google Scholar]12.
Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol. 2011;137:1409–1418. 10.1007/s00432-011-1039-4. [Abstract] [CrossRef] [Google Scholar]13.
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer. 2009;9:153–166. 10.1038/nrc2602. [Abstract] [CrossRef] [Google Scholar]14.
Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006;24:1770–1783. 10.1200/JCO.2005.03.7689. [Abstract] [CrossRef] [Google Scholar]16.
Osoegawa, A. et al. Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. Investig. New Drugs41, 183–192 (2023). [Abstract]17.
Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-mutated non-small cell lung cancer: From mechanisms to new therapeutic strategies. Cancers. 2022;14:3337. 10.3390/cancers14143337. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]19.
Tadesse S, Caldon EC, Tilley W, Wang S. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J. Medicinal Chem. 2018;62:4233–4251. 10.1021/acs.jmedchem.8b01469. [Abstract] [CrossRef] [Google Scholar]20.
Xi M, et al. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. Eur. J. Medicinal Chem. 2019;164:77–91. 10.1016/j.ejmech.2018.11.076. [Abstract] [CrossRef] [Google Scholar]21.
Eyvazi S, et al. CDK9 as an appealing target for therapeutic interventions. Curr. Drug targets. 2019;20:453–464. 10.2174/1389450119666181026152221. [Abstract] [CrossRef] [Google Scholar]22.
Sánchez-Martínez C, Lallena MJ, Sanfeliciano SG, de Dios A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019) Bioorg. Medicinal Chem. Lett. 2019;29:126637. 10.1016/j.bmcl.2019.126637. [Abstract] [CrossRef] [Google Scholar]25.
Krek W, Nigg EA. Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. EMBO J. 1991;10:3331–3341. 10.1002/j.1460-2075.1991.tb04897.x. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]26.
Solomon MJ, Glotzer M, Lee TH, Philippe M, Kirschner MW. Cyclin activation of p34cdc2. Cell. 1990;63:1013–1024. 10.1016/0092-8674(90)90504-8. [Abstract] [CrossRef] [Google Scholar]27.
Timofeev O, Cizmecioglu O, Settele F, Kempf T, Hoffmann I. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J. Biol. Chem. 2010;285:16978–16990. 10.1074/jbc.M109.096552. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]28.
Sarhan AR, et al. LAR protein tyrosine phosphatase regulates focal adhesions through CDK1. J. Cell Sci. 2016;129:2962–2971. [Abstract] [Google Scholar]31.
Chen M-S, Ryan CE, Piwnica-Worms H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol. Cell. Biol. 2003;23:7488–7497. 10.1128/MCB.23.21.7488-7497.2003. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]32.
Timofeev O, Cizmecioglu O, Hu E, Orlik T, Hoffmann I. Human Cdc25A phosphatase has a non-redundant function in G2 phase by activating Cyclin A-dependent kinases. FEBS Lett. 2009;583:841–847. 10.1016/j.febslet.2009.01.044. [Abstract] [CrossRef] [Google Scholar]33.
Honda R, Ohba Y, Nagata A, Okayama H, Yasuda H. Dephosphorylation of human p34 cdc2 kinase on both Thr‐14 and Tyr‐15 by human cdc25B phosphatase. FEBS Lett. 1993;318:331–334. 10.1016/0014-5793(93)80540-B. [Abstract] [CrossRef] [Google Scholar]34.
Kumagai A, Dunphy WG. Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science. 1996;273:1377–1380. 10.1126/science.273.5280.1377. [Abstract] [CrossRef] [Google Scholar]35.
Lee MH, et al. Menadione induces G2/M arrest in gastric cancer cells by down-regulation of CDC25C and proteasome mediated degradation of CDK1 and cyclin B1. Am. J. Transl. Res. 2016;8:5246. [Europe PMC free article] [Abstract] [Google Scholar]38.
Flores-Delgado G, Liu CW, Sposto R, Berndt N. A limited screen for protein interactions reveals new roles for protein phosphatase 1 in cell cycle control and apoptosis. J. Proteome Res. 2007;6:1165–1175. 10.1021/pr060504h. [Abstract] [CrossRef] [Google Scholar]40.
Huang R, et al. BECN1 promotes radiation-induced G2/M arrest through regulation CDK1 activity: a potential role for autophagy in G2/M checkpoint. Cell Death Discov. 2020;6:1–17. 10.1038/s41420-020-00301-2. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]43.
Park JH, Bang SW, Kim SH, Hwang DS. Knockdown of human MCM10 activates G2 checkpoint pathway. Biochemical Biophys. Res. Commun. 2008;365:490–495. 10.1016/j.bbrc.2007.11.004. [Abstract] [CrossRef] [Google Scholar]44.
Hirota T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell. 2003;114:585–598. 10.1016/S0092-8674(03)00642-1. [Abstract] [CrossRef] [Google Scholar]45.
Yalcin A, et al. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis. 2014;5:e1337–e1337. 10.1038/cddis.2014.292. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]46.
Kabuta T, et al. Ubiquitin C-terminal hydrolase L1 (UCH-L1) acts as a novel potentiator of cyclin-dependent kinases to enhance cell proliferation independently of its hydrolase activity. J. Biol. Chem. 2013;288:12615–12626. 10.1074/jbc.M112.435701. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]47.
Voets E, Wolthuis RM. MASTL is the human ortholog of Greatwall kinase that facilitates mitotic entry, anaphase and cytokinesis. Cell Cycle. 2010;9:3591–3601. 10.4161/cc.9.17.12832. [Abstract] [CrossRef] [Google Scholar]48.
Li Y, Lau YC. TSPY and its X-encoded homologue interact with cyclin B but exert contrasting functions on cyclin-dependent kinase 1 activities. Oncogene. 2008;27:6141–6150. 10.1038/onc.2008.206. [Abstract] [CrossRef] [Google Scholar]50.
Erez A, et al. The SIL gene is essential for mitotic entry and survival of cancer cells. Cancer Res. 2007;67:4022–4027. 10.1158/0008-5472.CAN-07-0064. [Abstract] [CrossRef] [Google Scholar]53.
Schmit F, Cremer S, Gaubatz S. LIN54 is an essential core subunit of the DREAM/LINC complex that binds to the cdc2 promoter in a sequence‐specific manner. FEBS J. 2009;276:5703–5716. 10.1111/j.1742-4658.2009.07261.x. [Abstract] [CrossRef] [Google Scholar]54.
Fang X, Xie M, Liu X, He Y. CENPE contributes to pulmonary vascular remodeling in pulmonary hypertension. Biochem. Biophys. Res. Commun. 2021;557:40–47. 10.1016/j.bbrc.2021.04.010. [Abstract] [CrossRef] [Google Scholar]55.
Vizcaíno C, Mansilla S, Portugal J. Sp1 transcription factor: A long-standing target in cancer chemotherapy. Pharmacol. Therapeutics. 2015;152:111–124. 10.1016/j.pharmthera.2015.05.008. [Abstract] [CrossRef] [Google Scholar]59.
Son Y, Kwon SM, Cho JY. CD276 (B7‐H3) Maintains proliferation and regulates differentiation in angiogenic function in late endothelial progenitor cells. Stem Cells. 2019;37:382–394. 10.1002/stem.2944. [Abstract] [CrossRef] [Google Scholar]62.
Liberman N, Marash L, Kimchi A. The translation initiation factor DAP5 is a regulator of cell survival during mitosis. Cell Cycle. 2009;8:204–209. 10.4161/cc.8.2.7384. [Abstract] [CrossRef] [Google Scholar]66.
Yang Y, Dai Y, Yang X, Wu S, Wang Y. DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction between EZH2 and DNMT3A. Biomolecules. 2021;11:781. 10.3390/biom11060781. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]67.
Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science. 1992;257:1955–1957. 10.1126/science.1384126. [Abstract] [CrossRef] [Google Scholar]68.
Wicky S, Tjandra H, Schieltz D, Yates J, III, Kellogg DR. The Zds proteins control entry into mitosis and target protein phosphatase 2A to the Cdc25 phosphatase. Mol. Biol. cell. 2011;22:20–32. 10.1091/mbc.e10-06-0487. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]69.
Knight GL, Turnell AS, Roberts S. Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins. J. Virol. 2006;80:7416–7426. 10.1128/JVI.00196-06. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]70.
Liu F, Stanton JJ, Wu Z, Piwnica-Worms H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol. Cell. Biol. 1997;17:571–583. 10.1128/MCB.17.2.571. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]71.
Chow JPH, Poon RYC. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene. 2013;32:4778–4788. 10.1038/onc.2012.504. [Abstract] [CrossRef] [Google Scholar]72.
Rohe A, et al. In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase. Bioorg. Medicinal Chem. Lett. 2012;22:1219–1223. 10.1016/j.bmcl.2011.11.064. [Abstract] [CrossRef] [Google Scholar]73.
Matheson CJ, Backos DS, Reigan P. Targeting WEE1 kinase in cancer. Trends Pharmacol. Sci. 2016;37:872–881. 10.1016/j.tips.2016.06.006. [Abstract] [CrossRef] [Google Scholar]74.
Liu Y-L, et al. Genistein induces G2/M arrest in gastric cancer cells by increasing the tumor suppressor PTEN expression. Nutr. Cancer. 2013;65:1034–1041. 10.1080/01635581.2013.810290. [Abstract] [CrossRef] [Google Scholar]78.
Yu Y, et al. Inhibition of KIF22 suppresses cancer cell proliferation by delaying mitotic exit through upregulating CDC25C expression. Carcinogenesis. 2014;35:1416–1425. 10.1093/carcin/bgu065. [Abstract] [CrossRef] [Google Scholar]80.
Kurabe N, et al. The death effector domain-containing DEDD supports S6K1 activity via preventing Cdk1-dependent inhibitory phosphorylation. J. Biol. Chem. 2009;284:5050–5055. 10.1074/jbc.M808598200. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]81.
Schreiber A, Peter M. Substrate recognition in selective autophagy and the ubiquitin–proteasome system. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 2014;1843:163–181. 10.1016/j.bbamcr.2013.03.019. [Abstract] [CrossRef] [Google Scholar]82.
Yoon CH, Miah MA, Kim KP, Bae YS. New Cdc2 Tyr 4 phosphorylation by dsRNA‐activated protein kinase triggers Cdc2 polyubiquitination and G2 arrest under genotoxic stresses. EMBO Rep. 2010;11:393–399. 10.1038/embor.2010.45. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]85.
Kawaguchi Y, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727–738. 10.1016/S0092-8674(03)00939-5. [Abstract] [CrossRef] [Google Scholar]88.
Chicheportiche Y, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 1997;272:32401–32410. 10.1074/jbc.272.51.32401. [Abstract] [CrossRef] [Google Scholar]90.
Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature. 1999;401:616–620. 10.1038/44188. [Abstract] [CrossRef] [Google Scholar]92.
Tanguay P-L, Rodier G, Meloche S. C-terminal domain phosphorylation of ERK3 controlled by Cdk1 and Cdc14 regulates its stability in mitosis. Biochem. J. 2010;428:103–111. 10.1042/BJ20091604. [Abstract] [CrossRef] [Google Scholar]93.
Gao, X. et al. Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer. Mol. Oncol.15, 1901–1920 (2021). [Europe PMC free article] [Abstract]94.
Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc. Natl Acad. Sci. 2006;103:15969–15974. 10.1073/pnas.0604193103. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]96.
Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Science’s STKE. 2005;2005:re12–re12. [Abstract] [Google Scholar]102.
Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol. Cell. Biol. 2004;24:2649–2661. 10.1128/MCB.24.7.2649-2661.2004. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]103.
Shi Q, et al. Phosphorylation of islet-1 serine 269 by CDK1 increases its transcriptional activity and promotes cell proliferation in gastric cancer. Mol. Med. 2021;27:1–11. 10.1186/s10020-021-00302-6. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]104.
Velásquez C, et al. Mitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformation. Proc. Natl Acad. Sci. 2016;113:8466–8471. 10.1073/pnas.1607768113. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]105.
Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer. 2003;3:859–868. 10.1038/nrc1209. [Abstract] [CrossRef] [Google Scholar]108.
Qiao M, et al. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J. Biol. Chem. 2006;281:7118–7128. 10.1074/jbc.M508162200. [Abstract] [CrossRef] [Google Scholar]109.
Adam-Stitah S, Penna L, Chambon P, Rochette-Egly C. Hyperphosphorylation of the retinoid X receptor α by activated c-Jun NH2-terminal kinases. J. Biol. Chem. 1999;274:18932–18941. 10.1074/jbc.274.27.18932. [Abstract] [CrossRef] [Google Scholar]113.
Kim HJ, et al. Cyclin-dependent kinase 1 activity coordinates the chromatin associated state of Oct4 during cell cycle in embryonic stem cells. Nucleic Acids Res. 2018;46:6544–6560. 10.1093/nar/gky371. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]114.
Terrano DT, Upreti M, Chambers TC. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell. Biol. 2010;30:640–656. 10.1128/MCB.00882-09. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]115.
Sakurikar N, Eichhorn JM, Chambers TC. Cyclin-dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of antiapoptotic Bcl-2 proteins. J. Biol. Chem. 2012;287:39193–39204. 10.1074/jbc.M112.391854. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]116.
Choi HJ, Zhu BT. Role of cyclin B1/Cdc2 in mediating Bcl‐XL phosphorylation and apoptotic cell death following nocodazole‐induced mitotic arrest. Mol. Carcinogenesis. 2014;53:125–137. 10.1002/mc.21956. [Abstract] [CrossRef] [Google Scholar]117.
LeBlanc FR, et al. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia. Cancer Biol. Ther. 2015;16:1830–1840. 10.1080/15384047.2015.1078949. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]118.
Darweesh, O. et al. Identification of a novel Bax–Cdk1 signalling complex that links activation of the mitotic checkpoint to apoptosis. J. Cell Sci.134 (2021). [Abstract]119.
Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J. Biol. Chem. 2007;282:11521–11529. 10.1074/jbc.M607279200. [Abstract] [CrossRef] [Google Scholar]120.
Zaja I, et al. Cdk1, PKCδ and calcineurin-mediated Drp1 pathway contributes to mitochondrial fission-induced cardiomyocyte death. Biochem. Biophys. Res. Commun. 2014;453:710–721. 10.1016/j.bbrc.2014.09.144. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]121.
Tailor D, Hahm E-R, Kale RK, Singh SV, Singh RP. Sodium butyrate induces DRP1-mediated mitochondrial fusion and apoptosis in human colorectal cancer cells. Mitochondrion. 2014;16:55–64. 10.1016/j.mito.2013.10.004. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]122.
Cepeda D, et al. CDK‐mediated activation of the SCFFBXO 28 ubiquitin ligase promotes MYC‐driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol. Med. 2013;5:1067–1086. 10.1002/emmm.201202341. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]123.
Nakajima T, et al. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2. J. Biol. Chem. 2015;290:10368–10381. 10.1074/jbc.M114.613018. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]124.
Bunz F, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282:1497–1501. 10.1126/science.282.5393.1497. [Abstract] [CrossRef] [Google Scholar]126.
Gaiddon C, et al. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J. Biol. Chem. 2003;278:27421–27431. 10.1074/jbc.M300251200. [Abstract] [CrossRef] [Google Scholar]127.
Yuan Z, et al. Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science. 2008;319:1665–1668. 10.1126/science.1152337. [Abstract] [CrossRef] [Google Scholar]128.
Liu P, Kao T, Huang H. CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene. 2008;27:4733–4744. 10.1038/onc.2008.104. [Abstract] [CrossRef] [Google Scholar]130.
Allan LA, Clarke PR. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol. Cell. 2007;26:301–310. 10.1016/j.molcel.2007.03.019. [Abstract] [CrossRef] [Google Scholar]131.
Narayan N, Massimi P, Banks L. CDK phosphorylation of the discs large tumour suppressor controls its localisation and stability. J. Cell Sci. 2009;122:65–74. 10.1242/jcs.024554. [Abstract] [CrossRef] [Google Scholar]132.
Margottin-Goguet F, et al. Prophase destruction of Emi1 by the SCFβTrCP/Slimb ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev. Cell. 2003;4:813–826. 10.1016/S1534-5807(03)00153-9. [Abstract] [CrossRef] [Google Scholar]133.
Linares JF, Amanchy R, Diaz-Meco MT, Moscat J. Phosphorylation of p62 by cdk1 controls the timely transit of cells through mitosis and tumor cell proliferation. Mol. Cell. Biol. 2011;31:105–117. 10.1128/MCB.00620-10. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]134.
Miao H, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat. Cell Biol. 2001;3:527–530. 10.1038/35074604. [Abstract] [CrossRef] [Google Scholar]135.
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem. Biophys. Res. Commun. 2004;320:1096–1102. 10.1016/j.bbrc.2004.06.054. [Abstract] [CrossRef] [Google Scholar]136.
Zeng Y, et al. Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity. J. Biol. Chem. 2017;292:15028–15038. 10.1074/jbc.M117.796284. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]137.
Cho HJ, et al. Cdk1 protein-mediated phosphorylation of receptor-associated protein 80 (RAP80) serine 677 modulates DNA damage-induced G2/M checkpoint and cell survival. J. Biol. Chem. 2013;288:3768–3776. 10.1074/jbc.M112.401299. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]138.
Schwarz MA, Thornton J, Xu H, Awasthi N, Schwarz RE. Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide II. PLoS ONE. 2012;7:e33101. 10.1371/journal.pone.0033101. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]139.
Fung, T. K. & Poon, R. Y. Semin. Cell Dev. Biol.16, 335–342 (Elsevier). [Abstract]140.
Thomas Y, et al. Cdk1 phosphorylates SPAT-1/Bora to promote Plk1 activation in C. elegans and human cells. Cell Rep. 2016;15:510–518. 10.1016/j.celrep.2016.03.049. [Abstract] [CrossRef] [Google Scholar]141.
Liu J, Wang XN, Cheng F, Liou Y-C, Deng L-W. Phosphorylation of mixed lineage leukemia 5 by CDC2 affects its cellular distribution and is required for mitotic entry. J. Biol. Chem. 2010;285:20904–20914. 10.1074/jbc.M109.098558. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]143.
Rodriguez-Rodriguez J-A, Moyano Y, Játiva S, Queralt E. Mitotic exit function of Polo-like kinase Cdc5 is dependent on sequential activation by Cdk1. Cell Rep. 2016;15:2050–2062. 10.1016/j.celrep.2016.04.079. [Abstract] [CrossRef] [Google Scholar]144.
Yu Z, et al. Dynamic phosphorylation of CENP-A at Ser68 orchestrates its cell-cycle-dependent deposition at centromeres. Dev. Cell. 2015;32:68–81. 10.1016/j.devcel.2014.11.030. [Abstract] [CrossRef] [Google Scholar]148.
Zhang Q, et al. Ska3 phosphorylated by Cdk1 binds Ndc80 and recruits Ska to kinetochores to promote mitotic progression. Curr. Biol. 2017;27:1477–1484.e1474. 10.1016/j.cub.2017.03.060. [Abstract] [CrossRef] [Google Scholar]149.
Busti S, et al. Overexpression of Far1, a cyclin-dependent kinase inhibitor, induces a large transcriptional reprogramming in which RNA synthesis senses Far1 in a Sfp1-mediated way. Biotechnol. Adv. 2012;30:185–201. 10.1016/j.biotechadv.2011.09.007. [Abstract] [CrossRef] [Google Scholar]153.
Granata M, et al. Dynamics of Rad9 chromatin binding and checkpoint function are mediated by its dimerization and are cell cycle–regulated by CDK1 activity. PLoS Genet. 2010;6:e1001047. 10.1371/journal.pgen.1001047. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]154.
McKerlie M, Walker JR, Mitchell TR, Wilson FR, Zhu X-D. Phosphorylated (pT371) TRF1 is recruited to sites of DNA damage to facilitate homologous recombination and checkpoint activation. Nucleic Acids Res. 2013;41:10268–10282. 10.1093/nar/gkt775. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]159.
Wu CX, et al. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 2018;8:3737. 10.7150/thno.25487. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]160.
Park S, et al. CGP74514A enhances TRAIL-induced apoptosis in breast cancer cells by reducing X-linked inhibitor of apoptosis protein. Anticancer Res. 2014;34:3557–3562. [Abstract] [Google Scholar]161.
Larsson DE, et al. Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. Anticancer Res. 2006;26:4125–4129. [Abstract] [Google Scholar]162. Seufferlein, T., Kestler, A., Beutel, A., Perkhofer, L. & Ettrich, T. Translational Pancreatic Cancer Research 219–232 (Springer, 2020).
163.
Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr. Treat. Options Oncol. 2017;18:17. 10.1007/s11864-017-0456-2. [Abstract] [CrossRef] [Google Scholar]165.
Bose P, Grant S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk. Res. 2014;38:862–865. 10.1016/j.leukres.2014.06.007. [Abstract] [CrossRef] [Google Scholar]166.
Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res. 1999;5:2925–2938. [Abstract] [Google Scholar]167.
Motwani M, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin. Cancer Res. 2001;7:4209–4219. [Abstract] [Google Scholar]168.
Aklilu M, Kindler H, Donehower R, Mani S, Vokes E. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann. Oncol. 2003;14:1270–1273. 10.1093/annonc/mdg343. [Abstract] [CrossRef] [Google Scholar]169.
Schwartz GK, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol. 2002;20:2157–2170. 10.1200/JCO.2002.08.080. [Abstract] [CrossRef] [Google Scholar]171.
Cho BC, et al. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer. 2018;123:14–21. 10.1016/j.lungcan.2018.04.022. [Abstract] [CrossRef] [Google Scholar]172.
Reck M, et al. Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer. J. Thorac. Oncol. 2019;14:701–711. 10.1016/j.jtho.2019.01.010. [Abstract] [CrossRef] [Google Scholar]173. Hirte, H. et al. A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. Cancer Res. 67, 4368 (2007).
174.
Stone, A., Sutherland, R. L. & Musgrove, E. A. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit. Rev. Oncogenesis17 (2012). [Abstract]175.
Cassaday RD, et al. A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Clin. Lymphoma Myeloma Leuk. 2015;15:392–397. 10.1016/j.clml.2015.02.021. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]176.
Flynn J, et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015;29:1524–1529. 10.1038/leu.2015.31. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]177.
Kumar SK, et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood, J. Am. Soc. Hematol. 2015;125:443–448. [Europe PMC free article] [Abstract] [Google Scholar]178.
Mita MM, et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin. Breast Cancer. 2014;14:169–176. 10.1016/j.clbc.2013.10.016. [Abstract] [CrossRef] [Google Scholar]179.
Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol. Cancer Therapeutics. 2009;8:324–332. 10.1158/1535-7163.MCT-08-0890. [Abstract] [CrossRef] [Google Scholar]180.
Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol. Cancer Therapeutics. 2010;9:920–928. 10.1158/1535-7163.MCT-09-1071. [Abstract] [CrossRef] [Google Scholar]181.
Chen E, et al. A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. Br. J. Cancer. 2014;111:2262–2267. 10.1038/bjc.2014.565. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]182.
Do KT, et al. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2020;86:815–827. 10.1007/s00280-020-04176-z. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]183.
Phelps MA, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, J. Am. Soc. Hematol. 2009;113:2637–2645. [Europe PMC free article] [Abstract] [Google Scholar]184.
Lin TS, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J. Clin. Oncol. 2009;27:6012. 10.1200/JCO.2009.22.6944. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]185. Gregory, G. et al. Antitumor activity of pembrolizumab plus dinaciclib in patients with diffuse large B cell lymphoma: the phase 1B Keynote-155 study (2019).
186.
Stephenson JJ, et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer. 2014;83:219–223. 10.1016/j.lungcan.2013.11.020. [Abstract] [CrossRef] [Google Scholar]188.
Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer. 2014;14:1–13. 10.1186/1471-2407-14-32. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]189.
Xia Q, et al. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. Int. J. Oncol. 2014;44:735–744. 10.3892/ijo.2013.2240. [Abstract] [CrossRef] [Google Scholar]191.
Fabre C, et al. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemother. Pharmacol. 2014;74:1057–1064. 10.1007/s00280-014-2583-9. [Abstract] [CrossRef] [Google Scholar]192.
Mita MM, et al. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br. J. Cancer. 2017;117:1258–1268. 10.1038/bjc.2017.288. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]193.
Nemunaitis JJ, et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J. Transl. Med. 2013;11:1–14. 10.1186/1479-5876-11-259. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]194.
Sasayama T, et al. Over‐expression of Aurora‐A targets cytoplasmic polyadenylation element binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1. Genes Cells. 2005;10:627–638. 10.1111/j.1365-2443.2005.00870.x. [Abstract] [CrossRef] [Google Scholar]195.
Chen J, et al. Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathway. Int. J. Oncol. 2016;48:1628–1638. 10.3892/ijo.2016.3366. [Abstract] [CrossRef] [Google Scholar]196.
Zhang B, et al. TPX2 mediates prostate cancer epithelial-mesenchymal transition through CDK1 regulated phosphorylation of ERK/GSK3β/SNAIL pathway. Biochem. Biophys. Res. Commun. 2021;546:1–6. 10.1016/j.bbrc.2021.01.106. [Abstract] [CrossRef] [Google Scholar]197.
Yang Y, et al. c-Myc regulates the CDK1/cyclin B1 dependent-G2/M cell cycle progression by histone H4 acetylation in Raji cells Corrigendum in/10.3892/ijmm. 2019.4318. Int. J. Mol. Med. 2018;41:3366–3378. [Europe PMC free article] [Abstract] [Google Scholar]198.
Maimaiti A, Aizezi A, Anniwaer J. Zinc finger of the cerebellum 5 promotes colorectal cancer cell proliferation and cell cycle progression through enhanced CDK1/CDC25c signaling. Arch. Med. Sci.: AMS. 2021;17:449. 10.5114/aoms.2019.89677. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]199.
Gao CL, Wang GW, Yang GQ, Yang H, Zhuang L. Karyopherin subunit-α 2 expression accelerates cell cycle progression by upregulating CCNB2 and CDK1 in hepatocellular carcinoma. Oncol. Lett. 2018;15:2815–2820. [Europe PMC free article] [Abstract] [Google Scholar]200.
Li Q, Wang W, Hu Y-C, Yin T-T, He J. Knockdown of ubiquitin associated protein 2-like (UBAP2L) inhibits growth and metastasis of hepatocellular carcinoma. Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res. 2018;24:7109. 10.12659/MSM.912861. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]201.
Zhang X, Pan Y, Fu H, Zhang J. Nucleolar and spindle associated protein 1 (NUSAP1) inhibits cell proliferation and enhances susceptibility to epirubicin in invasive breast cancer cells by regulating cyclin D kinase (CDK1) and DLGAP5 expression. Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res. 2018;24:8553. 10.12659/MSM.910364. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]202.
Jang Y-J, Ma S, Terada Y, Erikson RL. Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase. J. Biol. Chem. 2002;277:44115–44120. 10.1074/jbc.M202172200. [Abstract] [CrossRef] [Google Scholar]203.
Ito Y, et al. Polo-like kinase 1 (PLK1) expression is associated with cell proliferative activity and cdc2 expression in malignant lymphoma of the thyroid. Anticancer Res. 2004;24:259–264. [Abstract] [Google Scholar]204. Liu, W., Zhang, R., Li, E., Wu, L. & Wang, J. IFITM3 regulates NCAPG through phosphorylation to influence the invasion and metastasis of HCC. 10.21203/rs.3.rs-54017/v1 (2020).
205.
Yi X, Li Y, Zai H, Long X, Li W. KLF8 knockdown triggered growth inhibition and induced cell phase arrest in human pancreatic cancer cells. Gene. 2016;585:22–27. 10.1016/j.gene.2016.03.025. [Abstract] [CrossRef] [Google Scholar]207.
Qu G-q, et al. Effect of RTKN on progression and metastasis of colon cancer in vitro. Biomedicine Pharmacother. 2015;74:117–123. 10.1016/j.biopha.2015.07.012. [Abstract] [CrossRef] [Google Scholar]208.
Ishitsuka Y, et al. Pituitary tumor-transforming gene 1 enhances proliferation and suppresses early differentiation of keratinocytes. J. investigative Dermatol. 2012;132:1775–1784. 10.1038/jid.2012.74. [Abstract] [CrossRef] [Google Scholar]210.
Chiu H-C, et al. Suppression of vimentin phosphorylation by the avian reovirus p17 through inhibition of CDK1 and Plk1 impacting the G2/M phase of the cell cycle. PLoS ONE. 2016;11:e0162356. 10.1371/journal.pone.0162356. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]211.
Hsieh WL, et al. IFI27, a novel epidermal growth factor‐stabilized protein, is functionally involved in proliferation and cell cycling of human epidermal keratinocytes. Cell Prolif. 2015;48:187–197. 10.1111/cpr.12168. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]213.
Park S-Y, et al. Depletion of BubR1 promotes premature centrosomal localization of cyclin B1 and accelerates mitotic entry. Cell Cycle. 2009;8:1754–1764. 10.4161/cc.8.11.8671. [Abstract] [CrossRef] [Google Scholar]214.
Liu W, Li W, Fujita T, Yang Q, Wan Y. Proteolysis of CDH1 enhances susceptibility to UV radiation-induced apoptosis. Carcinogenesis. 2008;29:263–272. 10.1093/carcin/bgm251. [Abstract] [CrossRef] [Google Scholar]215.
Yde C, Olsen B, Meek D, Watanabe N, Guerra B. The regulatory β-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis. Oncogene. 2008;27:4986–4997. 10.1038/onc.2008.146. [Abstract] [CrossRef] [Google Scholar]216.
LaGory EL, Sitailo LA, Denning MF. The protein kinase Cδ catalytic fragment is critical for maintenance of the G2/M DNA damage checkpoint. J. Biol. Chem. 2010;285:1879–1887. 10.1074/jbc.M109.055392. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]217.
Ovejero-Benito MC, Frade JM. Brain-derived neurotrophic factor-dependent cdk1 inhibition prevents G2/M progression in differentiating tetraploid neurons. PLoS ONE. 2013;8:e64890. 10.1371/journal.pone.0064890. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]218.
Schmidt A-K, et al. The p53/p73-p21 CIP1 tumor suppressor axis guards against chromosomal instability by restraining CDK1 in human cancer cells. Oncogene. 2021;40:436–451. 10.1038/s41388-020-01524-4. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]220.
Carujo S, et al. Glyceraldehyde 3-phosphate dehydrogenase is a SET-binding protein and regulates cyclin B-cdk1 activity. Oncogene. 2006;25:4033–4042. 10.1038/sj.onc.1209433. [Abstract] [CrossRef] [Google Scholar]221.
Canela N, et al. The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J. Biol. Chem. 2003;278:1158–1164. 10.1074/jbc.M207497200. [Abstract] [CrossRef] [Google Scholar]222.
Bury M, et al. NFE2L3 controls colon cancer cell growth through regulation of DUX4, a CDK1 inhibitor. Cell Rep. 2019;29:1469–1481.e1469. 10.1016/j.celrep.2019.09.087. [Abstract] [CrossRef] [Google Scholar]223.
Paruthiyil S, et al. Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res. Treat. 2011;129:777–784. 10.1007/s10549-010-1273-5. [Abstract] [CrossRef] [Google Scholar]224.
Toyo-oka K, et al. Protein phosphatase 4 catalytic subunit regulates Cdk1 activity and microtubule organization via NDEL1 dephosphorylation. J. Cell Biol. 2008;180:1133–1147. 10.1083/jcb.200705148. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]225.
Buffone MG, Schindler K, Schultz RM. Over-expression of CDC14B causes mitotic arrest and inhibits zygotic genome activation in mouse preimplantation embryos. Cell Cycle. 2009;8:3904–3913. 10.4161/cc.8.23.10074. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]227.
Ullah Z, Kohn MJ, Yagi R, Vassilev LT, DePamphilis ML. Differentiation of trophoblast stem cells into giant cells is triggered by p57/Kip2 inhibition of CDK1 activity. Genes Dev. 2008;22:3024–3036. 10.1101/gad.1718108. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]230.
Yim H, Erikson RL. Cell division cycle 6, a mitotic substrate of polo-like kinase 1, regulates chromosomal segregation mediated by cyclin-dependent kinase 1 and separase. Proc. Natl Acad. Sci. 2010;107:19742–19747. 10.1073/pnas.1013557107. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]231.
Sabour Alaoui S, et al. TWEAK affects keratinocyte G2/M growth arrest and induces apoptosis through the translocation of the AIF protein to the nucleus. PLoS ONE. 2012;7:e33609. 10.1371/journal.pone.0033609. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]234.
Roskoski R., Jr Src kinase regulation by phosphorylation and dephosphorylation. Biochem. Biophys. Res. Commun. 2005;331:1–14. 10.1016/j.bbrc.2005.03.012. [Abstract] [CrossRef] [Google Scholar]236.
Chen Y-J, et al. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J. Biol. Chem. 2009;284:30695–30707. 10.1074/jbc.M109.007997. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]237.
Rajgopal A, et al. Mitotic control of RUNX2 phosphorylation by both CDK1/cyclin B kinase and PP1/PP2A phosphatase in osteoblastic cells. J. Cell. Biochem. 2007;100:1509–1517. 10.1002/jcb.21137. [Abstract] [CrossRef] [Google Scholar]238.
Dobrikov MI, Shveygert M, Brown MC, Gromeier M. Mitotic phosphorylation of eukaryotic initiation factor 4G1 (eIF4G1) at Ser1232 by Cdk1: cyclin B inhibits eIF4A helicase complex binding with RNA. Mol. Cell. Biol. 2014;34:439–451. 10.1128/MCB.01046-13. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]239.
Fabbro M, et al. Cdk1/Erk2-and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev. cell. 2005;9:477–488. 10.1016/j.devcel.2005.09.003. [Abstract] [CrossRef] [Google Scholar]240.
Zhang T, Prives C. Cyclin a-CDK phosphorylation regulates MDM2 protein interactions. J. Biol. Chem. 2001;276:29702–29710. 10.1074/jbc.M011326200. [Abstract] [CrossRef] [Google Scholar]243.
Wei Y, et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol. 2011;13:87–94. 10.1038/ncb2139. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]244.
Matthess Y, Raab M, Knecht R, Becker S, Strebhardt K. Sequential Cdk1 and Plk1 phosphorylation of caspase-8 triggers apoptotic cell death during mitosis. Mol. Oncol. 2014;8:596–608. 10.1016/j.molonc.2013.12.013. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]245.
Kaibori Y, Saito Y, Nakayama Y. EphA2 phosphorylation at Ser897 by the Cdk1/MEK/ERK/RSK pathway regulates M‐phase progression via maintenance of cortical rigidity. FASEB J. 2019;33:5334–5349. 10.1096/fj.201801519RR. [Abstract] [CrossRef] [Google Scholar]246.
Garate M, Campos EI, Bush JA, Xiao H, Li G. Phosphorylation of the tumor suppressor p33ING1b at Ser‐126 influences its protein stability and proliferation of melanoma cells. FASEB J. 2007;21:3705–3716. 10.1096/fj.07-8069com. [Abstract] [CrossRef] [Google Scholar]247.
Takata H, Madung M, Katoh K, Fukui K. Cdk1-dependent phosphorylation of KIF4A at S1186 triggers lateral chromosome compaction during early mitosis. PLoS ONE. 2018;13:e0209614. 10.1371/journal.pone.0209614. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]250.
Shi X, et al. Phosphorylation of STAT3 serine-727 by cyclin-dependent kinase 1 is critical for nocodazole-induced mitotic arrest. Biochemistry. 2006;45:5857–5867. 10.1021/bi052490j. [Abstract] [CrossRef] [Google Scholar]251.
Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl‐1 by CDK1–cyclin B1 initiates its Cdc20‐dependent destruction during mitotic arrest. EMBO J. 2010;29:2407–2420. 10.1038/emboj.2010.112. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]254.
Heald R, McKeon F. Mutations of phosphorylation sites in lamin A that prevent nuclear lamina disassembly in mitosis. Cell. 1990;61:579–589. 10.1016/0092-8674(90)90470-Y. [Abstract] [CrossRef] [Google Scholar]255.
Luo J, et al. The microtubule-associated protein EML3 regulates mitotic spindle assembly by recruiting the Augmin complex to spindle microtubules. J. Biol. Chem. 2019;294:5643–5656. 10.1074/jbc.RA118.007164. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]258.
Nishimura K, et al. Cdk1-mediated DIAPH1 phosphorylation maintains metaphase cortical tension and inactivates the spindle assembly checkpoint at anaphase. Nat. Commun. 2019;10:1–12. 10.1038/s41467-019-08957-w. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]259.
Wu Z, Jiang Q, Clarke PR, Zhang C. Phosphorylation of Crm1 by CDK1–cyclin-B promotes Ran-dependent mitotic spindle assembly. J. Cell Sci. 2013;126:3417–3428. [Abstract] [Google Scholar]262.
Zhang X, et al. Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the γTuRC to the centrosome. J. Cell Sci. 2009;122:2240–2251. 10.1242/jcs.042747. [Abstract] [CrossRef] [Google Scholar]264.
Schofield AV, Gamell C, Suryadinata R, Sarcevic B, Bernard O. Tubulin polymerization promoting protein 1 (Tppp1) phosphorylation by Rho-associated coiled-coil kinase (rock) and cyclin-dependent kinase 1 (Cdk1) inhibits microtubule dynamics to increase cell proliferation. J. Biol. Chem. 2013;288:7907–7917. 10.1074/jbc.M112.441048. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]265.
Mori Y, Inoue Y, Taniyama Y, Tanaka S, Terada Y. Phosphorylation of the centrosomal protein, Cep169, by Cdk1 promotes its dissociation from centrosomes in mitosis. Biochem. Biophys. Res. Commun. 2015;468:642–646. 10.1016/j.bbrc.2015.11.004. [Abstract] [CrossRef] [Google Scholar]266.
Hong KU, et al. Cdk1-cyclin B1-mediated phosphorylation of tumor-associated microtubule-associated protein/cytoskeleton-associated protein 2 in mitosis. J. Biol. Chem. 2009;284:16501–16512. 10.1074/jbc.M900257200. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]267.
Imami K, et al. Phosphorylation of the ribosomal protein RPL12/uL11 affects translation during mitosis. Mol. Cell. 2018;72:84–98. 10.1016/j.molcel.2018.08.019. [Abstract] [CrossRef] [Google Scholar]268.
Trinh AT, Kim SH, Chang H-Y, Mastrocola AS, Tibbetts RS. Cyclin-dependent kinase 1-dependent phosphorylation of cAMP response element-binding protein decreases chromatin occupancy. J. Biol. Chem. 2013;288:23765–23775. 10.1074/jbc.M113.464057. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]269.
Yang H-C, et al. Pin1-mediated Sp1 phosphorylation by CDK1 increases Sp1 stability and decreases its DNA-binding activity during mitosis. Nucleic Acids Res. 2014;42:13573–13587. 10.1093/nar/gku1145. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]275.
Sun C, Zheng J, Cheng S, Feng D, He J. EBP50 phosphorylation by Cdc2/Cyclin B kinase affects actin cytoskeleton reorganization and regulates functions of human breast cancer cell line MDA-MB-231. Mol. Cells. 2013;36:47–54. 10.1007/s10059-013-0014-0. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]276.
Cukier IH, Li Y, Lee JM. Cyclin B1/Cdk1 binds and phosphorylates Filamin A and regulates its ability to cross-link actin. FEBS Lett. 2007;581:1661–1672. 10.1016/j.febslet.2007.03.041. [Abstract] [CrossRef] [Google Scholar]278.
Marceaux C, Petit D, Bertoglio J, David MD. Phosphorylation of ARHGAP19 by CDK1 and ROCK regulates its subcellular localization and function during mitosis. J. Cell Sci. 2018;131:jcs208397. 10.1242/jcs.208397. [Abstract] [CrossRef] [Google Scholar]280.
Nakamura A, Naito M, Arai H, Fujita N. Mitotic phosphorylation of Aki1 at Ser208 by cyclin B1–Cdk1 complex. Biochem. Biophys. Res. Commun. 2010;393:872–876. 10.1016/j.bbrc.2010.02.103. [Abstract] [CrossRef] [Google Scholar]281.
Diao A, Frost L, Morohashi Y, Lowe M. Coordination of golgin tethering and SNARE assembly: GM130 binds syntaxin 5 in a p115-regulated manner. J. Biol. Chem. 2008;283:6957–6967. 10.1074/jbc.M708401200. [Abstract] [CrossRef] [Google Scholar]284.
Borton MT, Rashid MS, Dreier MR, Taylor WR. Multiple levels of regulation of Sororin by Cdk1 and Aurora B. J. Cell. Biochem. 2016;117:351–360. 10.1002/jcb.25277. [Abstract] [CrossRef] [Google Scholar]285.
Shah OJ, Ghosh S, Hunter T. Mitotic regulation of ribosomal S6 kinase 1 involves Ser/Thr, Pro phosphorylation of consensus and non-consensus sites by Cdc2. J. Biol. Chem. 2003;278:16433–16442. 10.1074/jbc.M300435200. [Abstract] [CrossRef] [Google Scholar]286.
Bassermann F, et al. Multisite Phosphorylation of Nuclear Interaction Partner of ALK (NIPA) at G2/M Involves Cyclin B1/Cdk1*♦ J. Biol. Chem. 2007;282:15965–15972. 10.1074/jbc.M610819200. [Abstract] [CrossRef] [Google Scholar]287.
Estey MP, et al. Mitotic regulation of SEPT9 protein by cyclin-dependent kinase 1 (Cdk1) and Pin1 protein is important for the completion of cytokinesis. J. Biol. Chem. 2013;288:30075–30086. 10.1074/jbc.M113.474932. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]288.
Koseoglu MM, Graves LM, Marzluff WF. Phosphorylation of threonine 61 by cyclin a/Cdk1 triggers degradation of stem-loop binding protein at the end of S phase. Mol. Cell. Biol. 2008;28:4469–4479. 10.1128/MCB.01416-07. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]289.
Meijer L, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin‐dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997;243:527–536. 10.1111/j.1432-1033.1997.t01-2-00527.x. [Abstract] [CrossRef] [Google Scholar]291.
Yang X, Li H, Liu XS, Deng A, Liu X. Cdc2-mediated phosphorylation of CLIP-170 is essential for its inhibition of centrosome reduplication. J. Biol. Chem. 2009;284:28775–28782. 10.1074/jbc.M109.017681. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]294.
Esteban V, Vázquez-Novelle MD, Calvo E, Bueno A, Sacristán MP. Human Cdc14A reverses CDK1 phosphorylation of Cdc25A on serines 115 and 320. Cell Cycle. 2006;5:2894–2898. 10.4161/cc.5.24.3566. [Abstract] [CrossRef] [Google Scholar]298.
Carlson CR, et al. CDK1-mediated phosphorylation of the RIIα regulatory subunit of PKA works as a molecular switch that promotes dissociation of RIIα from centrosomes at mitosis. J. Cell Sci. 2001;114:3243–3254. 10.1242/jcs.114.18.3243. [Abstract] [CrossRef] [Google Scholar]299.
Cunat S, et al. The cell cycle control protein cdc25C is present, and phosphorylated on serine 214 in the transition from germinal vesicle to metaphase II in human oocyte meiosis. Mol. Reprod. Dev.: Incorporating Gamete Res. 2008;75:1176–1184. 10.1002/mrd.20853. [Abstract] [CrossRef] [Google Scholar]300.
Leost M, et al. Paullones are potent inhibitors of glycogen synthase kinase‐3β and cyclin‐dependent kinase 5/p25. Eur. J. Biochem. 2000;267:5983–5994. 10.1046/j.1432-1327.2000.01673.x. [Abstract] [CrossRef] [Google Scholar]302.
Brooks EE, et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 1997;272:29207–29211. 10.1074/jbc.272.46.29207. [Abstract] [CrossRef] [Google Scholar]303.
Faber AC, Chiles TC. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas. Cell Cycle. 2007;6:2982–2989. 10.4161/cc.6.23.4994. [Abstract] [CrossRef] [Google Scholar]304.
Hoessel R, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999;1:60–67. 10.1038/9035. [Abstract] [CrossRef] [Google Scholar]306.
Lawrie AM, et al. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 1997;4:796–801. 10.1038/nsb1097-796. [Abstract] [CrossRef] [Google Scholar]308.
Meyer T, et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti‐proliferative as well as in vivo anti‐tumor activity. Int. J. Cancer. 1989;43:851–856. 10.1002/ijc.2910430519. [Abstract] [CrossRef] [Google Scholar]309.
Emanuel S, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005;65:9038–9046. 10.1158/0008-5472.CAN-05-0882. [Abstract] [CrossRef] [Google Scholar]310.
Edamatsu H, Gau C-L, Nemoto T, Guo L, Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene. 2000;19:3059–3068. 10.1038/sj.onc.1203625. [Abstract] [CrossRef] [Google Scholar]311.
Raynaud FI, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin. Cancer Res. 2005;11:4875–4887. 10.1158/1078-0432.CCR-04-2264. [Abstract] [CrossRef] [Google Scholar]312.
Mahadevan D, et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann. Oncol. 2011;22:2137–2143. 10.1093/annonc/mdq734. [Abstract] [CrossRef] [Google Scholar]313.
Kang M, et al. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS-032, on cervical cancer. Int. J. Oncol. 2018;53:703–712. [Abstract] [Google Scholar]314.
DePinto W, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol. Cancer therapeutics. 2006;5:2644–2658. 10.1158/1535-7163.MCT-06-0355. [Abstract] [CrossRef] [Google Scholar]315.
Lane ME, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001;61:6170–6177. [Abstract] [Google Scholar]316.
Uchiyama H, et al. Cyclin‐dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T‐cell leukemia Jurkat cells. Cancer Sci. 2010;101:728–734. 10.1111/j.1349-7006.2009.01449.x. [Abstract] [CrossRef] [Google Scholar]317.
Raghavan P, et al. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. Int. J. Radiat. Oncol.* Biol.* Phys. 2012;84:e507–e514. 10.1016/j.ijrobp.2012.05.035. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]318.
Payton M, et al. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res. 2006;66:4299–4308. 10.1158/0008-5472.CAN-05-2507. [Abstract] [CrossRef] [Google Scholar]319.
Rajput S, et al. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. Oncotarget. 2016;7:56864. 10.18632/oncotarget.10870. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]320.
Hu C, et al. Combined inhibition of cyclin-dependent kinases (Dinaciclib) and AKT (MK-2206) blocks pancreatic tumor growth and metastases in patient-derived xenograft models. Mol. Cancer Therapeutics. 2015;14:1532–1539. 10.1158/1535-7163.MCT-15-0028. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]321.
Latham AM, et al. In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis. PLoS ONE. 2014;9:e110997. 10.1371/journal.pone.0110997. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]323.
Kubo A, et al. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin. Cancer Res. 1999;5:4279–4286. [Abstract] [Google Scholar]324.
Verdaguer E, et al. 3-Amino thioacridone, a selective cyclin-dependent kinase 4 inhibitor, attenuates kainic acid-induced apoptosis in neurons. Neuroscience. 2003;120:599–603. 10.1016/S0306-4522(03)00424-X. [Abstract] [CrossRef] [Google Scholar]326.
Arris CE, et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Medicinal Chem. 2000;43:2797–2804. 10.1021/jm990628o. [Abstract] [CrossRef] [Google Scholar]327.
Rigas A, Robson C, Curtin N. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene. 2007;26:7611–7619. 10.1038/sj.onc.1210586. [Abstract] [CrossRef] [Google Scholar]328.
Chen X, et al. The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro. Int. J. Mol. Med. 2017;40:235–242. 10.3892/ijmm.2017.2989. [Abstract] [CrossRef] [Google Scholar]329.
Obakan P, Arısan ED, Özfiliz P, Çoker-Gürkan A, Palavan-Ünsal N. Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells. Mol. Biol. Rep. 2014;41:145–154. 10.1007/s11033-013-2847-1. [Abstract] [CrossRef] [Google Scholar]330.
Coker-Gürkan A, et al. Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and autophagy in a time-dependent manner in HCT116 colon cancer cells. Oncol. Rep. 2015;33:2761–2770. 10.3892/or.2015.3918. [Abstract] [CrossRef] [Google Scholar]331.
Hikita T, Oneyama C, Okada M. Purvalanol A, a CDK inhibitor, effectively suppresses Src‐mediated transformation by inhibiting both CDKs and c‐Src. Genes Cells. 2010;15:1051–1062. 10.1111/j.1365-2443.2010.01439.x. [Abstract] [CrossRef] [Google Scholar]332.
Li H, et al. KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway. Oncogene. 2015;34:1432–1441. 10.1038/onc.2014.49. [Abstract] [CrossRef] [Google Scholar]333.
Deng J-R, Mou F-L. CDK inhibitor BMS-265246 induces cell cycle arrest and apoptosis of liver cancer cells in vitro. TUMOR. 2018;38:189–195. [Google Scholar]335.
Benson C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. cancer. 2007;96:29–37. 10.1038/sj.bjc.6603509. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]336.
Wang, H. et al. Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship. Eur. J. Medicinal Chem.223, 113652 (2021). [Abstract]Free full text in Europe PMC